Drugs / CSL-111
CSL-111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00395148 | Mar 2006 → Mar 2008 | diabetes mellitus, heart disorder | Bayside Health | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSL-111 | “Individuals with type 2 diabetes mellitus were infused with placebo or rHDL (CSL-111; 20 mg . kg(-1) . h(-1)) for 4 hours, resulting in an approximately 1.4-fold increase in...” PMID 19901191 ↗ Nov 2009 |
| Known as | reconstituted high-density lipoprotein | “We recently demonstrated that reconstituted high-density lipoprotein (rHDL) modulates glucose metabolism in humans via both AMP-activated protein kinase (AMPK) in muscle and by...” PMID 21224289 ↗ Jan 2011 |
| Known as | rHDL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00395148 ↗ |
| Action | Activate | “rHDL reduced plasma glucose in patients with type 2 diabetes mellitus by increasing plasma insulin and activating AMP-activated protein kinase in skeletal muscle.” PMID 19349317 ↗ Apr 2009 |
| Route | Intravenous | “Thirteen patients with type 2 diabetes mellitus received both intravenous reconstituted HDL (rHDL: 80 mg/kg over 4 hours) and placebo on separate days in a double-blind,...” PMID 19349317 ↗ Apr 2009 |